Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study

(2018) Mario Fernández-Ruiz et al.   TRANSPLANT INTERNATIONAL

Decreased tacrolimus plasma concentrations during HCV therapy: a drug–drug interaction or is there an alternative explanation?

(2017) E.J. Smolders et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

(2016) Polina German et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

(2015) Brian J. Kirby et al.   CLINICAL PHARMACOKINETICS

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

(2015) Susanna Naggie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects

(2014) P. German et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease

(2013) Gregory D. Kirk et al.   ANNALS OF INTERNAL MEDICINE

Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis

(2013) Esther J. Aspinall et al.   CLINICAL INFECTIOUS DISEASES

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Role of CYP2B6 in Stereoselective Human Methadone Metabolism

(2009) Rheem A. Totah et al.   ANESTHESIOLOGY

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

(2009) W. D. Hanley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease Progression

(2009) Ting‐Yi Chen et al.   CLINICAL INFECTIOUS DISEASES

Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects

(2009) Sheng Deng et al.   CLINICAL THERAPEUTICS

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

(2008) M. Iwamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance

(2008) ED Kharasch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression

(2008) Hla-Hla Thein et al.   HEPATOLOGY

Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV‐Infected Men: A Prospective Cohort Study

(2008) Daniel S. Fierer et al.   JOURNAL OF INFECTIOUS DISEASES